Tranzyme refocus failure confirmed as TZP-102 crashes again
This article was originally published in Scrip
Tranzyme Pharma is stopping a second clinical trial with TZP-102, an oral ghrelin agonist, as a treatment for diabetic gastroporesis because it failed to outperform placebo.
You may also be interested in...
Allergan will pay $200m to exercise its option to buy Motus Therapeutics (formerly Rhythm Health) after what the pharma described as a successful Phase IIb study for relamorelin in diabetic gastroparesis.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.